Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0P7LP
|
|||
| Drug Name |
Azetidine derivative 3
|
|||
| Synonyms |
PMID26161824-Compound-173
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Obesity [ICD-11: 5B81; ICD-10: E66; ICD-9: 278] | Patented | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C28H28Cl2F3N3O4S
|
|||
| Canonical SMILES |
CC(CO)NC(=O)C1=CC(=CC(=C1)N(C2CN(C2)C(C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)Cl)S(=O)(=O)C)C(F)(F)F
|
|||
| InChI |
1S/C28H28Cl2F3N3O4S/c1-17(16-37)34-27(38)20-11-21(28(31,32)33)13-24(12-20)36(41(2,39)40)25-14-35(15-25)26(18-3-7-22(29)8-4-18)19-5-9-23(30)10-6-19/h3-13,17,25-26,37H,14-16H2,1-2H3,(H,34,38)
|
|||
| InChIKey |
CVPMSFUZFFYDBR-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cannabinoid receptor 1 (CB1) | Target Info | Antagonist | [1] |
| Target's Patent Info | Cannabinoid receptor 1 (CB1) | Target's Patent Info | [1] | |
| KEGG Pathway | Rap1 signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Retrograde endocannabinoid signaling | ||||
| Panther Pathway | Endogenous cannabinoid signaling | |||
| Pathway Interaction Database | N-cadherin signaling events | |||
| Reactome | Class A/1 (Rhodopsin-like receptors) | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Small Ligand GPCRs | ||||
| BDNF signaling pathway | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.